Ro15-4513

Ro15-4513
Clinical data
Drug classGABAA receptor inverse agonist
ATC code
  • None
Identifiers
  • Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H14N6O3
Molar mass326.316 g·mol−1
3D model (JSmol)
  • O=C(OCC)C1=C2CN(C)C(C3=CC(N=[N+]=[N-])=CC=C3N2C=N1)=O
  • InChI=1S/C15H14N6O3/c1-3-24-15(23)13-12-7-20(2)14(22)10-6-9(18-19-16)4-5-11(10)21(12)8-17-13/h4-6,8H,3,7H2,1-2H3 checkY
  • Key:CFSOJZTUTOQNIA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s.[1] It acts as an inverse agonist (which acts in a similar way as a competitive antagonist), and can therefore be an antidote to the acute impairment caused by alcohols, including ethanol, isopropanol, tert-butyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, methylpentynol, and ethchlorvynol.

Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil.

  1. ^ US patent 4868176, Gardner CR, Hedgecook JR, "Novel imidazobenzodiazepines", issued 1989-09-19, assigned to Roussel Uclaf